News

The PicoAMH Elisa test, which measures the amount of Anti-Müllerian Hormone in the blood, was supported by data assessing 690 women.

Treating the blood clotting disorder thrombotic thrombocytopenic purpura might be possible through the use of a therapeutic enzyme.

The SynchroMed II myPTM Personal Therapy Manager allows patients with chronic pain to manage unpredictable pain by delivering on-demand doses within limits set by their provider.

The single-dose, oral therapy becomes the first new influenza antiviral with a novel mechanism of action approved by the FDA in nearly 20 years.

Switching antiepileptic drug manufacturer was found to increase the risk of seizure recurrence in a German population, contrary to findings in the US.

Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.

Men with Fabry disease develop white matter lesions much quicker than their female counterparts.

The vaccine is designed to help protect patients against a pair of both influenza A strain and B strain viruses. It is currently available in the US for the 2018-19 flu season.

Positive phase 2b data from AbbVie’s upadacitinib demonstrated an induction for clinical remission in patients with ulcerative colitis.

The investigators determined that hepatitis C co-infection increased risk for all-cause mortality in patients with HIV receiving antiretroviral treatment by 4.3%.

Mathematical modeling projects that Australia could achieve World Health Organization targets for elimination of HCV in a decade. What can the US learn from their efforts?

The most reliable practice for helping a patient quit is comprehensive, and catered to their medical, physical, and financial goals.

A supplemental new drug application (sNDA) for vortioxetine (TRINTELLIX), a prescription medication for the treatment of adults with major depressive disorder (MDD), has been accepted by the FDA.

Patients with inappropriate medication use lived farther from their preferred pharmacy than those with appropriate use—a median distance difference of just more than 1 mile.

Interferon‐α2 and ruxolitinib combination therapy shows promise in treating myeloproliferative neoplasms, according to recent preliminary findings.

Increased access to proper mental health care is a key weapon in the battle against the deadly opioid epidemic, according to a recent study.

People with depression exhibit an unexpected increase in volume on the left side of the hypothalamus, the brain region responsible for physical wellbeing.

New data suggest hepatitis C infection, but not hepatitis B infection, increases the prevalence of diabetes in patients who undergo kidney transplants.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Coverage of the post-surgery pain management therapy's strength has overlooked its clinical setting use and potential need.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The interleukin pathway-targeting monoclonal antibody has been previously approved for adult atopic dermatitis, and is being considered for a handful more inflammatory or allergic conditions.

From August 2014 to September 2018, a total of 386 confirmed cases of acute flaccid myelitis across the United States has been confirmed by the CDC.

Since AHC is a rare neurological disease, finding a diagnosis can be a harrowing experience.

The effect of a carbapenem on VPA is significant and may result in reduced efficacy and increased seizure activity. Because of the mechanism of this interaction, increasing the dose of the VPA will unlikely achieve therapeutic plasma concentrations.

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

These non-critical items are often used on multiple patients, and a lack of knowledge about proper cleaning and disinfection could contribute to the spread of C difficile.

People who are addicted to drugs face a higher risk of contracting HCV. Yet, a new study suggests the majority teens who are addicted to opioids don’t get screened for the virus.